Seoul, South Korea

Chong-Woo Park

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Chong-Woo Park in Pharmaceutical Composition

Introduction

Chong-Woo Park is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions aimed at treating various diseases. With a total of 2 patents, his work focuses on innovative solutions for retinal and diabetic conditions.

Latest Patents

Chong-Woo Park's latest patents include a pharmaceutical composition comprising an adenosine derivative for the prevention and treatment of retinal disease or optic nerve disease. This invention relates to a pharmaceutical composition, an oral administration agent, and an eye drop that effectively prevent or treat retinal diseases or optic nerve diseases. The active ingredient is represented by a specific chemical formula or a pharmaceutically acceptable salt thereof. Another significant patent is a pharmaceutical composition for preventing and treating diabetic nephropathy, which also includes an adenosine derivative compound as an active ingredient.

Career Highlights

Chong-Woo Park is currently associated with Future Medicine Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing effective treatments that address critical health issues.

Collaborations

Chong-Woo Park collaborates with talented individuals such as Mi Ra Yu and Bo Mi Park, contributing to a dynamic research environment that fosters innovation.

Conclusion

Chong-Woo Park's contributions to pharmaceutical compositions demonstrate his dedication to advancing medical science. His innovative patents reflect a commitment to improving health outcomes for patients suffering from retinal and diabetic conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…